Cite
MLA Citation
Michael Schiff et al.. “Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study.” RMD open, vol. 1, no. 1, 2015, p. . http://access.bl.uk/ark:/81055/vdc_100137793482.0x000003